For background on the forces that drove the industry consolidation, explore our Industry & Regulatory section in the Research Library.
The wave of peptide vendor closures that defined 2025 has slowed. The shakeout isn’t over, but the most acute phase is behind us. What remains is a smaller, more concentrated market, and understanding what separated the survivors from the casualties tells researchers more about sourcing quality than any marketing claim will.
The vendors that closed shared recognizable characteristics. Most competed on price rather than documentation. Most sourced from a narrow range of overseas suppliers without backup options. Most depended on one or two high-volume compounds with complicated legal footing. When customs enforcement tightened, when payment processors exited, and when regulatory pressure intensified, those structural weaknesses became fatal simultaneously.
The vendors that survived built differently. Broad compound catalogs reduced exposure to any single regulatory decision. Established supplier relationships with documented compliance processes absorbed supply chain disruption that closed thinner operations. Third-party COA documentation on every batch gave payment processors and customers a reason to stay. These aren’t coincidental features of the survivors; they’re the reasons they survived.
The regulatory picture as of April 2026 remains unsettled but directionally clearer than it was twelve months ago. HHS Secretary RFK Jr. announced in February that approximately 14 of the 19 peptides on the FDA’s Category 2 restricted list would be moved back to Category 1, restoring legal compounding access through licensed pharmacies with a prescription. No formal FDA rule change has been published as of this writing. The announcement signals the direction of policy without yet changing the law. Researchers who moved on to those compounds based on the announcement alone are ahead of the formal regulatory reality.
For the research community, the practical implication is straightforward. The vendors worth trusting in the current market are the ones that were worth trusting before the shakeout. Sourcing decisions should still be made on documentation, not survival. A vendor that made it to 2026 by cutting corners on testing is not a better option than one that didn’t make it while maintaining quality. The criteria haven’t changed. The pool of candidates has just gotten smaller.
BioStrata supplies research-grade compounds with full third-party COA documentation for every batch. BPC-157 is available for laboratory research use. The full compound catalog is at the BioStrata shop.
FDA Enforcement on Peptide Companies Is Accelerating in 2026 — Peptide Drug Summit
FDA Peptide Ban Lifted: 14 Peptides Reclassified in 2026 — Peptide Journal